Recombinant DNA immunotherapy ameliorate established airway allergy in a IL-10 dependent pathway (2012)
- Authors:
- USP affiliated authors: RUSSO, MOMTCHILO - ICB ; RAMOS, SIMONE GUSMÃO - FMRP ; BARUFFI, MARCELO DIAS - FCFRP ; GEMBRE, ANA FLÁVIA - FMRP ; MARTINS, VANIA LUIZA DEPERON BONATO - FMRP
- Unidades: ICB; FMRP; FCFRP
- DOI: 10.1111/j.1365-2222.2011.03845.x
- Assunto: IMUNOLOGIA
- Language: Inglês
- Imprenta:
- Source:
- Título: Clinical and Experimental Allergy
- ISSN: 1365-2222
- Volume/Número/Paginação/Ano: v. 42, n. 1, p. 131-143, 2012
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
FONSECA, Denise Morais da et al. Recombinant DNA immunotherapy ameliorate established airway allergy in a IL-10 dependent pathway. Clinical and Experimental Allergy, v. 42, n. 1, p. 131-143, 2012Tradução . . Disponível em: https://doi.org/10.1111/j.1365-2222.2011.03845.x. Acesso em: 18 fev. 2026. -
APA
Fonseca, D. M. da, Wowk, P. F., Paula, M. O., Campos, L. W., Gembre, A. F., Turato, W. M., et al. (2012). Recombinant DNA immunotherapy ameliorate established airway allergy in a IL-10 dependent pathway. Clinical and Experimental Allergy, 42( 1), 131-143. doi:10.1111/j.1365-2222.2011.03845.x -
NLM
Fonseca DM da, Wowk PF, Paula MO, Campos LW, Gembre AF, Turato WM, Ramos SG, Dias-Baruffi M, Barboza R, Gomes E, Silva CL, Russo M, Bonato VLD. Recombinant DNA immunotherapy ameliorate established airway allergy in a IL-10 dependent pathway [Internet]. Clinical and Experimental Allergy. 2012 ; 42( 1): 131-143.[citado 2026 fev. 18 ] Available from: https://doi.org/10.1111/j.1365-2222.2011.03845.x -
Vancouver
Fonseca DM da, Wowk PF, Paula MO, Campos LW, Gembre AF, Turato WM, Ramos SG, Dias-Baruffi M, Barboza R, Gomes E, Silva CL, Russo M, Bonato VLD. Recombinant DNA immunotherapy ameliorate established airway allergy in a IL-10 dependent pathway [Internet]. Clinical and Experimental Allergy. 2012 ; 42( 1): 131-143.[citado 2026 fev. 18 ] Available from: https://doi.org/10.1111/j.1365-2222.2011.03845.x - IFN-'gama'-mediated efficacy of allergen-free immunotherapy using mycobacterial antigens and CpG-ODN
- Protection conferred by heterologous vaccination against tuberculosis is dependent on the ratio of CD4+/ CD4+ Foxp3+ cells
- M2 macrophages or IL-33 treatment attenuate ongoing Mycobacterium tuberculosis infection
- Leukotrienes are not essential for the efficacy of a heterologous vaccine against Mycobacterium tuberculosis infection
- Host genetic background affects regulatory T-cel activity that influences the magnitude of cellular immune response against Mycobacterium tuberculosis
- Requirement of MyD88 and Fas pathways for the efficacy of allergen-free immunotherapy
- Therapeutic and prophylactic effects of DNA-HSP65 in experimental allergy
- Mycobacterium tuberculosis culture filtrate proteins plus CpG oligodeoxynucleotides confer protection to mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion
- Antigen-presenting cells transfected with Hsp65 messenger RNA fail to treat experimental tuberculosis
- Attenuation of experimental asthma by mycobacterial protein combined with CpG requires a TLR9-dependent IFN-γ-CCR2 signalling circuit
Informações sobre o DOI: 10.1111/j.1365-2222.2011.03845.x (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
